SG11202105730TA - Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof - Google Patents

Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Info

Publication number: SG11202105730TA
Authority: SG; Singapore
Prior art keywords: benzamides; pyrazolyl; amino; compositions; methods
Prior art date: 2018-12-14

Application number

SG11202105730TA

Inventor

Zhaokui Wan

Michael Lawrence Vazquez

Xiaodong Li

Original Assignee

Lynk Pharmaceuticals Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-14

Filing date

2019-12-16

Publication date

2021-06-29

2019-12-16 Application filed by Lynk Pharmaceuticals Co Ltd filed Critical Lynk Pharmaceuticals Co Ltd

2021-06-29 Publication of SG11202105730TA publication Critical patent/SG11202105730TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pregnancy & Childbirth (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

SG11202105730TA 2018-12-14 2019-12-16 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof SG11202105730TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/CN2018/121165 WO2020118683A1 (en)	2018-12-14	2018-12-14	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
PCT/CN2019/125552 WO2020119819A1 (en)	2018-12-14	2019-12-16	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Publications (1)

Publication Number	Publication Date
SG11202105730TA true SG11202105730TA (en)	2021-06-29

Family

ID=71076270

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202105730TA SG11202105730TA (en)	2018-12-14	2019-12-16	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof

Country Status (14)

Country	Link
US (6)	US20230002362A1 (en)
EP (1)	EP3877381A4 (en)
JP (3)	JP7459094B2 (en)
KR (1)	KR20210125983A (en)
CN (7)	CN118903141A (en)
AU (3)	AU2019399939B2 (en)
BR (1)	BR112021011147A2 (en)
CA (3)	CA3122872A1 (en)
EA (1)	EA202191188A1 (en)
IL (3)	IL314086A (en)
MX (3)	MX2021006866A (en)
SG (1)	SG11202105730TA (en)
TW (3)	TWI866940B (en)
WO (2)	WO2020118683A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110627775A (en) *	2019-10-24	2019-12-31	嘉兴特科罗生物科技有限公司	Small molecule compound
WO2021204159A1 (en)	2020-04-08	2021-10-14	Agios Pharmaceuticals, Inc.	Menin inhibitors and methods of use for treating cancer
CN112661655B (en) *	2020-12-29	2022-02-18	江苏云朴医药新材料科技有限公司	1-aminomethyl-1-cyclopropanol compound and synthetic method thereof
IL318535A (en) *	2022-08-22	2025-03-01	Hangzhou Highlightll Pharmaceutical Co Ltd	Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases
CN115572269B (en) *	2022-10-08	2024-05-17	广州大学	N-trifluoroisopropylazole and indole compound and preparation method thereof
CN116751191A (en) *	2023-05-19	2023-09-15	凌科药业(杭州)有限公司	Crystal form, preparation method and application of pyrazolyl-amino-pyrimidinyl derivative
WO2023151724A1 (en) *	2023-05-19	2023-08-17	凌科药业(杭州)有限公司	Crystal form of pyrazolyl-amino-pyrimidinyl derivative, and preparation method therefor and use thereof
WO2024239282A1 (en) *	2023-05-24	2024-11-28	凌科药业(杭州)有限公司	Pharmaceutical composition, topical preparation, and preparation method therefor and use thereof
CN116983312B (en) *	2023-05-24	2024-07-05	凌科药业(杭州)有限公司	Pharmaceutical composition, external preparation, and preparation method and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007297754B2 (en) *	2006-09-18	2012-05-17	Vertex Pharmaceuticals Incorporated	Heterocyclic inhibitors of c-MET and uses thereof
WO2009017838A2 (en) *	2007-08-01	2009-02-05	Exelixis, Inc.	Combinations of jak-2 inhibitors and other agents
WO2009064835A1 (en) *	2007-11-16	2009-05-22	Incyte Corporation	4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CN103298794A (en) *	2010-11-09	2013-09-11	塞尔卓姆有限公司	Pyridine compounds and aza analogues thereof as TYK2 inhibitors
WO2012143320A1 (en) *	2011-04-18	2012-10-26	Cellzome Limited	(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
AU2012288892B2 (en) *	2011-07-28	2016-04-21	Cellzome Limited	Heterocyclyl pyrimidine analogues as JAK inhibitors
DE102011112978A1 (en) *	2011-09-09	2013-03-14	Merck Patent Gmbh	benzonitrile derivatives
KR101361149B1 (en) *	2012-07-17	2014-02-24	전남대학교산학협력단	Gene Implicated in Drought Stress Tolerance and Transformed Plants with the Same
HUE040346T2 (en) *	2013-12-11	2019-03-28	Biogen Ma Inc	In the field of oncology, neurology and immunology, biaryl compounds are useful in the treatment of human diseases
CN106349224A (en) *	2016-08-03	2017-01-25	山东大学	JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof
CN108864057B (en) *	2017-05-16	2020-03-31	山东大学	JAK and HDAC dual-target inhibitor containing 4-aminopyrazole structure and preparation method and application thereof
WO2020206588A1 (en) *	2019-04-08	2020-10-15	Lynk Pharmaceuticals Co., Ltd.	Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN110330484B (en) *	2019-07-18	2022-08-26	中国药科大学	Substituted phenyl pyrimidine derivative as JAK kinase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application
CN110627775A (en) *	2019-10-24	2019-12-31	嘉兴特科罗生物科技有限公司	Small molecule compound

2018
- 2018-12-14 WO PCT/CN2018/121165 patent/WO2020118683A1/en active Application Filing
2019
- 2019-12-13 TW TW108145807A patent/TWI866940B/en active
- 2019-12-13 TW TW113122616A patent/TW202440559A/en unknown
- 2019-12-13 TW TW113122615A patent/TW202440558A/en unknown
- 2019-12-16 CN CN202411028128.9A patent/CN118903141A/en active Pending
- 2019-12-16 IL IL314086A patent/IL314086A/en unknown
- 2019-12-16 EP EP19896790.3A patent/EP3877381A4/en active Pending
- 2019-12-16 IL IL314084A patent/IL314084A/en unknown
- 2019-12-16 SG SG11202105730TA patent/SG11202105730TA/en unknown
- 2019-12-16 CN CN202411028139.7A patent/CN119118999A/en active Pending
- 2019-12-16 BR BR112021011147-6A patent/BR112021011147A2/en unknown
- 2019-12-16 MX MX2021006866A patent/MX2021006866A/en unknown
- 2019-12-16 CN CN202411028131.0A patent/CN118903142A/en active Pending
- 2019-12-16 CA CA3122872A patent/CA3122872A1/en active Pending
- 2019-12-16 CA CA3230071A patent/CA3230071A1/en active Pending
- 2019-12-16 CN CN202410365639.3A patent/CN118388457A/en active Pending
- 2019-12-16 CA CA3230060A patent/CA3230060A1/en active Pending
- 2019-12-16 CN CN201980076141.2A patent/CN113227074B/en active Active
- 2019-12-16 CN CN202410365633.6A patent/CN118290403A/en active Pending
- 2019-12-16 KR KR1020217019621A patent/KR20210125983A/en active Pending
- 2019-12-16 WO PCT/CN2019/125552 patent/WO2020119819A1/en active Application Filing
- 2019-12-16 JP JP2021530299A patent/JP7459094B2/en active Active
- 2019-12-16 EA EA202191188A patent/EA202191188A1/en unknown
- 2019-12-16 AU AU2019399939A patent/AU2019399939B2/en active Active
- 2019-12-16 CN CN202411028121.7A patent/CN118955477A/en active Pending
2021
- 2021-06-10 MX MX2024005744A patent/MX2024005744A/en unknown
- 2021-06-10 MX MX2024005747A patent/MX2024005747A/en unknown
- 2021-06-14 IL IL283968A patent/IL283968A/en unknown
2022
- 2022-03-01 US US17/684,030 patent/US20230002362A1/en active Pending
- 2022-03-01 US US17/684,164 patent/US20220298144A1/en active Pending
2023
- 2023-09-10 US US18/244,276 patent/US12030870B2/en active Active
- 2023-09-10 US US18/244,281 patent/US11981663B2/en active Active
- 2023-09-24 US US18/372,115 patent/US12098142B2/en active Active
2024
- 2024-02-21 AU AU2024201125A patent/AU2024201125B2/en active Active
- 2024-02-21 AU AU2024201128A patent/AU2024201128B2/en active Active
- 2024-03-12 JP JP2024038370A patent/JP2024089673A/en active Pending
- 2024-03-12 JP JP2024038369A patent/JP2024088646A/en active Pending
- 2024-08-15 US US18/805,713 patent/US20250115586A1/en active Pending

Also Published As

Publication number	Publication date
IL314084A (en)	2024-09-01
US11981663B2 (en)	2024-05-14
CN118290403A (en)	2024-07-05
CN118955477A (en)	2024-11-15
US20240025882A1 (en)	2024-01-25
US20240083881A1 (en)	2024-03-14
US12098142B2 (en)	2024-09-24
AU2019399939A1 (en)	2021-06-24
AU2024201128A1 (en)	2024-03-14
MX2024005744A (en)	2024-05-28
CA3230060A1 (en)	2020-06-18
AU2024201125A1 (en)	2024-03-14
TW202440559A (en)	2024-10-16
WO2020119819A1 (en)	2020-06-18
CN118903141A (en)	2024-11-08
US20220298144A1 (en)	2022-09-22
US12030870B2 (en)	2024-07-09
BR112021011147A2 (en)	2021-08-31
JP2024088646A (en)	2024-07-02
TW202440558A (en)	2024-10-16
CA3230071A1 (en)	2020-06-18
EA202191188A1 (en)	2021-11-29
AU2024201125B2 (en)	2025-03-06
AU2019399939B2 (en)	2024-07-11
TWI866940B (en)	2024-12-21
EP3877381A1 (en)	2021-09-15
JP7459094B2 (en)	2024-04-01
CN119118999A (en)	2024-12-13
TW202039474A (en)	2020-11-01
WO2020118683A1 (en)	2020-06-18
US20250115586A1 (en)	2025-04-10
US20230416235A1 (en)	2023-12-28
JP2024089673A (en)	2024-07-03
US20230002362A1 (en)	2023-01-05
CN118388457A (en)	2024-07-26
MX2024005747A (en)	2024-05-28
EP3877381A4 (en)	2022-08-24
IL314086A (en)	2024-09-01
CA3122872A1 (en)	2020-06-18
AU2024201128B2 (en)	2025-03-06
CN118903142A (en)	2024-11-08
IL283968A (en)	2021-07-29
CN113227074B (en)	2024-08-16
MX2021006866A (en)	2021-11-17
CN113227074A (en)	2021-08-06
KR20210125983A (en)	2021-10-19
JP2022510925A (en)	2022-01-28

Publication	Publication Date	Title
IL274276A (en)	2020-06-30	Casz compositions and methods of use
SG11202105730TA (en)	2021-06-29	Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
IL280963A (en)	2021-04-29	Anti-gdf15 antibodies, compositions and methods of use
IL279422A (en)	2021-01-31	Polymerases, compositions, and methods of use
IL279423A (en)	2021-01-31	Polymerases, compositions, and methods of use
ZA202000608B (en)	2022-07-27	Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
GB2614634B (en)	2023-11-08	Cannabinoid compositions and methods of using
PL3668937T3 (en)	2023-08-07	Compositions and uses of z-1-chloro-2,3,3,3-tetrafluoroprop-1-ene
GB2582100B (en)	2023-05-17	CAS12C Compositions and methods of use
ZA202102034B (en)	2022-09-28	Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
EP3436061A4 (en)	2019-12-04	Saccharide-polypeptide conjugate compositions and methods of use thereof
IL289763A (en)	2022-03-01	Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
HK1259372A1 (en)	2019-11-29	Therapeutic compounds, compositions and methods of use thereof
ZA201906169B (en)	2021-01-27	Synthekine compositions and methods of use
IL244278A0 (en)	2016-07-31	Cannabinoid compositions, methods of manufacture and use thereof
IL282939A (en)	2021-06-30	Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
ZA202100780B (en)	2023-07-26	Bismuth-thiol compositions and methods of use
IL276135A (en)	2020-09-30	Compositions and methods of use
SG11202011227VA (en)	2020-12-30	Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
SG11202011041YA (en)	2020-12-30	Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
IL282533A (en)	2021-06-30	Oligosaccharide compositions and methods of use thereof
IL272834A (en)	2020-04-30	Amantadine compositions, preparations thereof, and methods of use
IL269884B1 (en)	2023-05-01	Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
EP3538126A4 (en)	2020-10-07	Bacteriocin production, compositions and methods of use
SG11202108262VA (en)	2021-08-30	Bacterialcidal methods and compositions